MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of Tie2 with IC50 of 1 nM, 3 nM, 3 nM, 4 nM, 2 nM and 7 nM, respectively.

In vitro MGCD-265 inhibits cell proliferation both in c-Met-driven tumor cells (MKN45, MNNG-HOS, and SNU-5) and in non-c-Met-driven tumor cells (HCT116 and MDA-MB-231), with IC50 values ranging from 1 nM to 7 nM. [1] MGCD-265 inhibits cell proliferation both in c-Met-driven tumor cells (MKN45, MNNG-HOS, and SNU-5) and in non-c-Met-driven tumor cells (HCT116 and MDA-MB-231), with IC50 values ranging from 1 nM to 7 nM. [1] MGCD-265 also inhibits cell proliferation in c-Met-driven tumor cells (MKN45, MNNG-HOS, and SNU-5) and in non-c-Met-driven tumor cells (HCT116 and MDA-MB-231), with IC50 values ranging from 1 nM to 7 nM. [1]

In vivo In c-Met-driven or non-c-Met-driven mice xenograft models of MKN45, U87MG, MDA-MB-231, COLO205, and A549 cells, MGCD-265 (20 mg/kg–60 mg/kg) inhibits tumor growth and c-Met signaling. MGCD-265 (40 nM–5 μM) effectively inhibits c-Met phosphorylation and its downstream signaling pathways, including Erk, Akt, Stat3, and Fak. MGCD-265 (6 nM–1 μM) also induces apoptosis in MKN45 cells. [2]

Clinical Trials A Phase I clinical trial of MGCD-265 in advanced malignancies has been completed. Currently, MGCD-265, in combination of erlotinib or docetaxel, is under investigation in a Phase I/II clinical trial for advanced malignancies or non-small cell lung cancer.

Features

Protocol (Only for Reference)

Cell Lines: HCT116, MDA-MB-231, SNU-5, and MKN45 cells
Concentrations: 0–5 μM
Incubation Time: 72 hours
Methods: Cells are treated with MGCD-265 for 72 hours and cell number is determined as a function of mitochondrial activity, following incubation with MTT for 4 hours.

Animal Study
Animal Models: Mice (CD-1 nude) xenograft models of MKN45, U87MG, MDA-MB-231, COLO205, and A549 cells
Doses: 20 mg/kg–60 mg/kg
Administration: Orally

References

Customer Reviews

C-Met Inhibitor MGCD265
PLEASE KEEP THE PRODUCT UNDER -20°C FOR LONG-TERM STORAGE.

NOT FOR HUMAN, VETERINARY_DIAGNOSTIC OR THERAPEUTIC USE

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality, but save your shipping charges by using the most economical storage conditions for an overnight shipment. Upon receipt of the product, follow the storage recommendations on the product datasheet.